Inovio Biomedical's DNA Vaccine Delivery Technology Moves Ahead in Clinical Trial for Hepatitis C
Inovio initiates 5th DNA vaccine clinical study: hepatitis C
Inovio Biomedical Corporation announced that its partner, Tripep AB of Sweden, has begun enrolling patients for its Phase I/II clinical study of a novel DNA vaccine designed to treat chronically infected hepatitis C virus (HCV) patients. The trial will test Tripep's proprietary DNA vaccine, ChronVac-C®, administered using Inovio's MedPulser® DNA Delivery System, in 12 subjects already infected with HCV. The trial is being conducted in Sweden at the world-renowned Karolinska Institute.
The main purpose of the study is to show that the treatment is safe, but also to test if the treatment boosts patients' immune response to hepatitis C and its effects on virus replication.
"This is the first human study in the world in which a DNA vaccine against an infectious disease is being administered by in vivo electroporation. We are enthusiastic that enrollment has started as planned," said Jan Nilsson, CEO of Tripep AB.
The study encompasses a total of 12 treatment naive patients with chronic hepatitis C virus infections of genotype 1 and with a low viral load. The patients will be divided into four dose groups. Each patient will receive four monthly vaccinations and then be monitored for another six months.
Other news from the department research and development
